Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Lee, Ji Hwan MD; Lee, Sung Chul MD; Kim, Seo Hee MD; Koh, Hyoung Jun MD; Kim, Sung Soo MD; Byeon, Suk Ho MD; Lee, Christopher Seungkyu MD

doi: 10.1097/IAE.0000000000001384
Original Study
Buy

Purpose: This study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti–vascular endothelial growth factor therapy.

Methods: Fifty eyes of 50 treatment-naive patients with myopic CNV who underwent anti–vascular endothelial growth factor monotherapy with at least 2 years of follow-up data were included. The cumulative occurrence of CRA progression was assessed using a Kaplan–Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression.

Results: The mean age was 52.34 years. A mean of 4.84 anti–vascular endothelial growth factor injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated occurrence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. Chorioretinal atrophy progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit.

Conclusion: Chorioretinal atrophy progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti–vascular endothelial growth factor therapy.

Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal choroidal neovascularization location may predispose eyes with myopic choroidal neovascularization to develop chorioretinal atrophy progression after anti–vascular endothelial growth factor therapy. Progression of chorioretinal atrophy was associated with a poor long-term prognosis.

Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea.

Reprint requests: Christopher Seungkyu Lee, MD, Department of Ophthalmology, Yonsei University College of Medicine, 134 Shinchondong, Seodaemungu, Seoul 03722, Republic of Korea; e-mail: sklee219@yuhs.ac

None of the authors has any financial/conflicting interests to disclose.

© 2017 by Ophthalmic Communications Society, Inc.